This document discusses TRI (transradial intervention) in patients with chronic kidney disease (CKD). It notes that CKD patients have accelerated atherosclerosis and are at high risk for coronary artery disease. While PCI can help treat CAD, CKD patients face higher risks of bleeding complications and renal impairment from the procedures. The document recommends hydration, low-osmolar contrast agents, and limiting contrast load when performing PCI in CKD patients to protect kidney function. It argues that TRI may reduce bleeding risks compared to transfemoral approaches but must be used cautiously in end-stage renal disease to avoid compromising existing or future arteriovenous fistulas needed for hemodialysis access.